Revelation Biosciences, Inc.·Healthcare

SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today announced formation of an Acute Kidney Injury (AKI) Advisory Board for the upcoming Phase 2/3 AKI clinical trial. This distinguished panel brings together internationally recognized Nephrologists and Critical Care Physicians who will guide the company's clinical strategy, monitor progress, and ensure the initiative achieves the goal of improving patient care by advancing Gemini for the treatment of AKI.

- A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on innovative solutions for acute and chronic disease, presented additional positive data analysis from the PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego (March 29 - April 1, 2026). Presented datademonstrated the capability of Gemini to normalize the hyperinflammatory state and restore immunocompetence up to 7 days after a single dose, in stage 3 and 4 chronic kidney disease (CKD) patients peripheral blood mononuclear cells.

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced a reminder of its participation in a fireside chat on Tuesday, March 24, 2026, at 2:00 p.m. PT, as part of the 38th Annual Roth Conference, in Dana Point, CA.

SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th.

Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 100,079 shares, a drop of 61.2% from the January 29th total of 258,211 shares. Based on an average daily volume of 372,176 shares,

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025. Corporate Highlights Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury Received net proceeds of $6.7 million from warrant inducement in January 2026 Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 - April 1, 2026) "2025 was a positive year for Revelation with significant advancement of the Gemini program," said James Rolke, Chief Executive Officer of Revelation.
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
Healthcare
Biotechnology
8
2020-11-17
-0.17